Aratana Therapeutics Inc., a development stage enterprise, was incorporated on December 1, 2010 under the laws of the State of Delaware. The Company had its initial public offering in June 2013. It is a biopharmaceutical company engaged in licensing or acquisition, development and commercialization of pharmaceutical products for pets. The Company has licensed and is developing three compounds: a selective prostaglandin E receptor 4, or EP4, antagonist, or AT-001, for the treatment of pain and inflammation associated with arthritis in dogs and for pain management in cats; a ghrelin agonist, or AT-002, for inappetance in cats and dogs; and a bupivacaine liposome injectable suspension, AT-003, for the treatment of post-operative pain in cats and dogs. Its current product portfolio includes over 15 product candidates consisting of small molecule pharmaceuticals and large molecule biologics in serious medical conditions in pets. From a development and commercialization perspective, AT-004 and AT-005 are monoclonal antibodies for treating lymphoma in dogs. AT-004, which treats B-cell lymphoma, received a conditional license from the U.S. Department of Agriculture and is currently marketed by Novartis Animal Health Inc. AT-005, which treats T-cell lymphoma, received a conditional license from the USDA and the Company expects to commence limited marketing of the product. The Company competes with other pharmaceutical, biotechnology and specialty animal health medicines companies. Its competitors include Zoetis, Inc.; Merck Animal Health; Merial, the animal health division of Sanofi S.A.; Elanco, the animal health division of Eli Lilly and Company; Bayer Animal Health; NAH, the animal health division of Novartis AG; Boehringer Ingelheim Animal Health; Virbac Group; Ceva Animal Health; Vetoquinol and Dechra Pharmaceuticals PLC. Further, the Company also will face competition from Rimadyl, marketed by Zoetis, and generic Carprofen, Deramaxx, marketed by NAH, Previcox, marketed by Merial, and Metacam, marketed by Boehringer Ingelheim, and generic Meloxicam if AT-001 is approved.